AG˹ٷ

STOCK TITAN

[Form 4] Gilead Sciences Inc Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences (GILD), reported an insider sale on Form 4. The filing shows a sale of 2,500 shares of Gilead common stock on 08/15/2025 at a price of $118.53 per share, leaving Mr. Dickinson with 160,110 shares beneficially owned after the transaction. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on 08/29/2024. The Form 4 was signed by Edward S. Son by power of attorney for Mr. Dickinson and dated 08/18/2025.

Andrew D. Dickinson, Chief Financial Officer di Gilead Sciences (GILD), ha comunicato una vendita da parte di un insider nel Modulo 4. La dichiarazione riporta la cessione di 2.500 azioni ordinarie di Gilead il 15/08/2025 al prezzo di 118,53 USD per azione, lasciando al signor Dickinson 160.110 azioni detenute utilmente dopo l’operazione. La vendita è stata effettuata nell’ambito di un piano di negoziazione Rule 10b5-1 adottato il 29/08/2024. Il Modulo 4 è stato firmato da Edward S. Son per procura per conto del sig. Dickinson e datato 18/08/2025.

Andrew D. Dickinson, Director Financiero de Gilead Sciences (GILD), declaró una venta de acciones por parte de un insider en el Formulario 4. El informe muestra la venta de 2.500 acciones ordinarias de Gilead el 15/08/2025 a 118,53 USD por acción, dejando al Sr. Dickinson con 160.110 acciones en propiedad beneficiosa tras la transacción. La venta se realizó conforme a un plan de negociación Rule 10b5-1 adoptado el 29/08/2024. El Formulario 4 fue firmado por Edward S. Son por poder notarial en nombre del Sr. Dickinson y fechado el 18/08/2025.

Gilead Sciences(GILD) 최고재무책임� Andrew D. Dickinson� Form 4� 내부� 매도 신고� 했습니다. 제출서에� 2025-08-15� Gilead 보통� 2,500주를 주당 118.53달러� 매도� 것으� 기재되어 있으�, 거래 � Dickinson 씨의 실질 소유 주식은 160,110�� 남아 있습니다. 해당 매도� 2024-08-29� 채택� Rule 10b5-1 거래 계획� 따라 이루어졌습니�. Form 4� Dickinson 씨의 위임� 받아 Edward S. Son� 서명했으� 날짜� 2025-08-18입니�.

Andrew D. Dickinson, directeur financier de Gilead Sciences (GILD), a déclaré une cession d’initié via le formulaire 4. Le dépôt indique la vente de 2 500 actions ordinaires Gilead le 15/08/2025 au prix de 118,53 USD par action, laissant M. Dickinson avec 160 110 actions en propriété bénéficiaire après la transaction. La vente a été réalisée en vertu d’un plan de négociation Rule 10b5-1 adopté le 29/08/2024. Le formulaire 4 a été signé par Edward S. Son par procuration pour M. Dickinson et daté du 18/08/2025.

Andrew D. Dickinson, Finanzvorstand von Gilead Sciences (GILD), meldete einen Insiderverkauf im Formular 4. Die Einreichung weist den Verkauf von 2.500 Gilead-Stammaktien am 15.08.2025 zu einem Preis von 118,53 USD je Aktie aus; nach der Transaktion hält Herr Dickinson weiterhin 160.110 Aktien wirtschaftlich. Der Verkauf erfolgte im Rahmen eines am 29.08.2024 eingeführten Rule 10b5-1-Handelsplans. Das Formular 4 wurde von Edward S. Son per Vollmacht für Herrn Dickinson unterzeichnet und ist auf den 18.08.2025 datiert.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine insider sale under a pre-established 10b5-1 plan; small relative size versus total holdings, likely neutral for investors.

The sale of 2,500 shares at $118.53 each appears to be executed under a Rule 10b5-1 plan, which typically indicates a pre-planned, non-discretionary transaction rather than opportunistic timing by management. After the sale, the CFO retains 160,110 shares, maintaining significant personal exposure to the company's stock. Given the limited size of the sale relative to the retained holdings, this disclosure is unlikely to materially change the investment thesis on its own.

TL;DR: Use of a 10b5-1 plan demonstrates adherence to insider trading controls; filing and POA signature are standard governance practices.

The Form 4 documents compliance with disclosure rules and shows the transaction was covered by a 10b5-1 trading plan adopted on August 29, 2024, which supports governance transparency. The form was executed by a power of attorney, a common administrative step. There are no indications of undisclosed or suspicious timing in the filing itself.

Andrew D. Dickinson, Chief Financial Officer di Gilead Sciences (GILD), ha comunicato una vendita da parte di un insider nel Modulo 4. La dichiarazione riporta la cessione di 2.500 azioni ordinarie di Gilead il 15/08/2025 al prezzo di 118,53 USD per azione, lasciando al signor Dickinson 160.110 azioni detenute utilmente dopo l’operazione. La vendita è stata effettuata nell’ambito di un piano di negoziazione Rule 10b5-1 adottato il 29/08/2024. Il Modulo 4 è stato firmato da Edward S. Son per procura per conto del sig. Dickinson e datato 18/08/2025.

Andrew D. Dickinson, Director Financiero de Gilead Sciences (GILD), declaró una venta de acciones por parte de un insider en el Formulario 4. El informe muestra la venta de 2.500 acciones ordinarias de Gilead el 15/08/2025 a 118,53 USD por acción, dejando al Sr. Dickinson con 160.110 acciones en propiedad beneficiosa tras la transacción. La venta se realizó conforme a un plan de negociación Rule 10b5-1 adoptado el 29/08/2024. El Formulario 4 fue firmado por Edward S. Son por poder notarial en nombre del Sr. Dickinson y fechado el 18/08/2025.

Gilead Sciences(GILD) 최고재무책임� Andrew D. Dickinson� Form 4� 내부� 매도 신고� 했습니다. 제출서에� 2025-08-15� Gilead 보통� 2,500주를 주당 118.53달러� 매도� 것으� 기재되어 있으�, 거래 � Dickinson 씨의 실질 소유 주식은 160,110�� 남아 있습니다. 해당 매도� 2024-08-29� 채택� Rule 10b5-1 거래 계획� 따라 이루어졌습니�. Form 4� Dickinson 씨의 위임� 받아 Edward S. Son� 서명했으� 날짜� 2025-08-18입니�.

Andrew D. Dickinson, directeur financier de Gilead Sciences (GILD), a déclaré une cession d’initié via le formulaire 4. Le dépôt indique la vente de 2 500 actions ordinaires Gilead le 15/08/2025 au prix de 118,53 USD par action, laissant M. Dickinson avec 160 110 actions en propriété bénéficiaire après la transaction. La vente a été réalisée en vertu d’un plan de négociation Rule 10b5-1 adopté le 29/08/2024. Le formulaire 4 a été signé par Edward S. Son par procuration pour M. Dickinson et daté du 18/08/2025.

Andrew D. Dickinson, Finanzvorstand von Gilead Sciences (GILD), meldete einen Insiderverkauf im Formular 4. Die Einreichung weist den Verkauf von 2.500 Gilead-Stammaktien am 15.08.2025 zu einem Preis von 118,53 USD je Aktie aus; nach der Transaktion hält Herr Dickinson weiterhin 160.110 Aktien wirtschaftlich. Der Verkauf erfolgte im Rahmen eines am 29.08.2024 eingeführten Rule 10b5-1-Handelsplans. Das Formular 4 wurde von Edward S. Son per Vollmacht für Herrn Dickinson unterzeichnet und ist auf den 18.08.2025 datiert.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dickinson Andrew D

(Last) (First) (Middle)
GILEAD SCIENCES, INC.
333 LAKESIDE DRIVE

(Street)
FOSTER CITY CA 94404

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/15/2025 S(1) 2,500 D $118.53 160,110 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
Remarks:
/s/ Edward S. Son by Power of Attorney for Andrew D. Dickinson 08/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Gilead Sciences Inc

NASDAQ:GILD

GILD Rankings

GILD Latest News

GILD Latest SEC Filings

GILD Stock Data

146.39B
1.24B
0.1%
90.91%
1.61%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
United States
FOSTER CITY